HIMSS CEO, president to retire at end of 2017

Stephen Lieber, longtime CEO and president of the Healthcare Information and Management Systems Society (HIMSS), has announced he’ll be retiring at the end of 2017. The search for his replacement has already begun.

Lieber has been at the helm of the 65,000-member healthcare technology trade group since 2000. The society’s press release credited his tenure as helping health IT be embraced as “a primary asset in addressing problems associated with the cost, quality and access of health and care.”

“The past 17 years at HIMSS have been the most exciting and rewarding time of my professional life,” Lieber said. “I feel that our work at HIMSS has resulted in considerable improvements to the quality of care delivered to patients, to the safety of the treatments they receive and to the value of care provided. I hope that, in some way, I can continue this work of making care better and safer through information technology.”

Executive search firm Egon Zehnder has been hired to find Lieber’s successor. The expectation is the replacement will be chosen by the summer of 2017 and will then serve alongside Lieber until the end of the year to “ensure a smooth transition.”

“HIMSS has seen tremendous growth in size, reach and influence during Steve’s leadership,” said Sebastian Krolop, MD, PhD, chairman of the HIMSS Board of Directors. “Steve has provided the right balance of strategic and operational leadership necessary for HIMSS to transform from a small, US-only based professional society to a large, globally focused diversified organization. I would therefore like to take this opportunity to express my deepest gratitude to Steve for his passion, constant dedication and outstanding efforts.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.